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It is known that neutropenia caused by combination 
pegylated interferon plus ribavirin therapy for hepatitis 
C virus (HCV) infection is well tolerated and carries a 
negligible risk of infection. Neutropenic enterocolitis is 
encountered most frequently in patients with hema-
to-oncologic diseases who are undergoing intensive 
chemotherapy. However, little information exists re-
garding this life-threatening event in the setting of 
HCV therapy. We present here an unusual case of 
fatal neutropenic enterocolitis in a cirrhotic patient re-
ceiving combination therapy for HCV infection. This is 
the first report of a death from neutropenic enter-
ocolitis associated with treatment for chronic HCV 
infection. The present case suggests that caution sh-
ould be exercised when continuing HCV therapy in 
neutropenic patients with advanced fibrosis, and the 
decision to maintain such therapy should be balanced 
against the potential for serious adverse events. (Gut 
and Liver 2009;3:218-221)
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INTRODUCTION
  Hepatitis C virus (HCV) infection, the major cause of 
chronic liver disease, cirrhosis, and liver cancer, affects 
approximately 170 million individuals worldwide.
1 Combi-
nation therapy with pegylated interferon (PEG-IFN) plus 
ribavirin has become the current standard regimen for pa-
tients with chronic hepatitis C. Such therapy is associated 
with overall sustained virologic response rates of 75% to 
90% among patients with HCV genotype 2 or 3 infection 
and  45% to 52% among those with genotype 1.
2 Recen-
tly, a new combination therapy together with thymosin 
alpha-1 has been investigated in difficult-to-treat patients 
to increase treatment response.
3 The therapy is associated 
with various side effects, especially hematologic abnor-
malities. Some studies suggest that PEG-IFN is commonly 
associated with a higher incidence of neutropenia com-
pared with standard IFN therapy.
4 Nevertheless, it is 
known that neutropenia during PEG-IFN therapy does not 
appear to be associated with serious sequela and seems 
to be effectively managed by dose modifications.
5
  Neutropenic enterocolitis is a life-threatening complica-
tion of intensive chemotherapy, and remains a clinical 
syndrome characterized by abdominal pain and fever in 
neutropenic patients. This disease entity has been most 
often described in patients with hematologic malignancies 
such as acute leukemia, multiple myeloma, and aplastic 
anemia, following chemotherapy.
6 In rare cases, this com-
plication has also been reported in the setting of solid 
cancer and autologous transplantation,
6 but almost never 
documented in patients with chronic hepatitis C. In this 
report, we describe a rare case of fatal neutropenic enter-
ocolitis encountered in a patient with chronic HCV in-
fection receiving PEG-IFN plus ribavirin combination 
therapy. 
CASE REPORT
  A 54-year-old man with known HCV infection was re-
ferred to our institution for treatment of chronic hepatitis Kim JH, et al: Neutropenic Enterocolitis during HCV Therapy   219
Fig. 1. Ultrasonography of the liver showing (A) a coarse echotexture of the parenchyma, an irregular nodular surface, and (B) 
splenomegaly (approximately 13 cm).
Fig. 2. Serial changes in the white blood cell count (WBC) and
absolute neutrophil counts (ANCs) after pegylated interferon 
and ribavirin combination therapy.
C. Pretreatment laboratory tests were as follows: elevated 
aspartate aminotransferase (AST) and alanine amino-
transferase (ALT) levels, 97 and 202 IU/L, respectively; 
total bilirubin level, 1.9 mg/dL; white blood cell (WBC) 
count, 5,400/mm
3; platelet count, 149,000/mm
3; pro-
thrombin time (INR), 1.21; genotype 2a; and HCV viral 
load, 371,000 IU/mL. There was no history of alcohol 
abuse, gastrointestinal diseases, other co-infectious dis-
eases, and metabolic diseases. Although a liver biopsy 
was not performed, an ultrasound examination of the liv-
er revealed a coarse echotexture of the parenchyma, an ir-
regular nodular surface, and splenomegaly (13 cm), to-
gether highly suggestive of cirrhosis (Fig. 1). A 24-week 
course of standard combination therapy with PEG-IFN al-
pha 2a 180 μg weekly and ribavirin 800 mg daily was 
planned. At week 12 of treatment, serum HCV RNA was 
negative, but AST and ALT levels remained elevated at 
approximately 2 times the upper limits of normal. The 
therapy was continued until week 22 without serious side 
effects, except a sustained weight loss of 15 kg, anorexia, 
and general weakness. Through 20 weeks of treatment, 
WBC counts of the patient were maintained between 
2,000 and 2,600/mm
3, with absolute neutrophil counts 
(ANC) ranging from 760 to 945/mm
3 (Fig. 2). After 22 
weeks of antiviral treatment, however, he complained of 
the sudden onset of diarrhea and abdominal pain with se-
vere tenderness over the right side of the abdomen. On 
admission to the hospital, his temperature was 39.1
oC, 
the pulse was 113/min and regular, the respiratory rate 
was 28/min, and the blood pressure was 90/50 mmHg. 
The laboratory findings included total WBC count, 
1,000/mm
3; ANC, 611/mm
3; platelet count, 41,000/mm
3; 
hemoglobin, 9.8 g/dL; and elevated liver enzymes (AST, 
217 IU/L and ALT, 117 IU/L). A computed tomography 
(CT) scan with contrast of the patient’s abdomen was ob-
tained and demonstrated marked edematous wall thicken-
ing of the ascending and proximal transverse colons, with 
pericolic strands (Fig. 3). Stool specimens were non-spe-
cific and negative for Clostridium difficile toxin. The diag-
nosis of neutropenic enterocolitis was made based on the 
presence of fever, abdominal pain, and bowel wall thicke-
ning. Broad spectrum antibiotics, inotropic support, and 
granulocyte colony-stimulating factor were administered 
immediately. Despite intensive antibiotic therapy and best 
supportive treatment, he continued to deteriorate and ul-
timately died from multiorgan failure on hospital day 9. 
The blood cultures were positive for Escherichia coli.220   Gut and Liver, Vol. 3, No. 3, September 2009
Fig. 3. CT scan on admission of a patient who presented with symptoms of neutropenic enterocolitis. (A) Edematous wall 
thickening of the ascending colon with pericolic strands. (B) Cirrhotic liver with minimal ascites in the perihepatic space, and 
splenomegaly.
DISCUSSION
  Neutropenic enterocolitis occurs most often following 
treatment of hematologic malignancies and high-dose che-
motherapy in solid tumors, and has a 5.3% pooled in-
cidence rate, with high mortality rates ranging from 50% 
to 100%.
7 Neutropenia is often observed in patients with 
chronic hepatitis C receiving PEG-IFN and ribavirin com-
bination therapy, but is generally well-tolerated without 
serious morbidities.
5 Moreover, intestinal complications 
associated with the combination therapy are rare, with 
only a few case reports of exacerbation of ulcerative col-
itis and ischemic colitis.
8-10 With regard to other in-
testinal events relevant to HCV therapy, a literature 
search found only one case of neutropenic enterocolitis 
which improved with empirical antibiotics and supportive 
care.
11 Thus, to the best of the authors’ knowledge, our 
patient is the second reported case to date and the first 
reported death from neutropenic enterocolitis while on 
HCV therapy.
  Neutropenic enterocolitis is highly suspected in neu-
tropenic patients presenting with fever and abdominal 
pain, especially in the right lower quadrant.
6 Abdominal 
imaging is useful in supporting a diagnosis of this 
disease. Some have suggested the criteria for the diag-
nosis of neutropenic enterocolitis to be fever, abdominal 
pain, and demonstration of the bowel wall thickening of 
more than 4 mm in any segment by ultrasound or CT 
scanning in a neutropenic state.
6 Our patient met all of 
these criteria, and the diagnosis of netropenic enter-
ocolitis in this case was therefore definite.
  Although the mechanism for the pathogenesis of neu-
tropenic enterocolitis is not completely understood, it is 
postulated that a combination of factors, including mu-
cosal injury by cytotoxic drugs, neutropenia, and impaired 
host defense to intestinal organisms progressing to bac-
teremia and sepsis, is responsible for the development of 
neutropenic enterocolitis.
6,12 Particularly, cirrhotic patients 
are at increased risk of bacterial infection because of in-
trinsic neutropenia, liver dysfunction, and reduced retic-
uloendothelial function. Thus, neutropenia during therapy 
of HCV infection can intensify the risk of infection in pa-
tients with HCV-related cirrhosis.
  Recently, it has been shown that a shorter course of 
PEG-IFN and ribavirin therapy over 12 weeks is as effec-
tive as a 24-week course for patients with HCV genotype 
2 or 3 who have a virologic response at 4 weeks.
13 It is 
unfortunate that in our case, HCV RNA at 4 weeks was 
not tested and the patient with HCV genotype 2a adhered 
so closely to a strict schedule of antiviral therapy. In ret-
rospect, the therapy could have been discontinued earlier 
if s e ru m  H C V  R N A  w a s  u n d e te c t a b le  a t w e e k  4  o f t h e r-
apy, taking into consideration the significant weight loss 
and anorexia in our patient.
  In conclusion, we believe this case report contains a 
worthwhile clinical lesson for practitioners who manage 
patients with chronic hepatitis C, especially those patients 
with advanced fibrosis or cirrhosis. Although some stud-
ies have indicated a negligible risk of infection associated 
with HCV treatment-related neutropenia,
5 caution should 
be exercised against serious infections when treating cir-
rhotic patients who are potentially immunocompromised. 
Although anorexia, weight loss and general weakness are 
non-specific adverse events of HCV combination therapy, 
if sustained and uncorrectable, clinicians should be aware 
of the potential development of neutropenic enterocolitis. Kim JH, et al: Neutropenic Enterocolitis during HCV Therapy   221
Furthermore, a shorter course of therapy could be consid-
e r e d  i n  a n  e f f o r t  t o  a v o i d  p o s s i b l e  s e v e r e  l if e - t h r e a t e n i n g 
side effects for those with cirrhosis who have had a rapid 
virologic response to therapy. 
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